



# **A Review on Impurity Profiling, Degradation Studies, and Bioanalytical Methods of Anti-diabetic Drugs**

**Mahesh M. Deshpande <sup>a\*</sup>, Madhuri H. Bhalerao <sup>a</sup> and Pooja D. Pabale <sup>a</sup>**

<sup>a</sup> *Department of Pharmaceutical Quality Assurance, Amrutvahini College of Pharmacy, Sangamner, M.S., India.*

## **Authors' contributions**

*This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.*

## **Article Information**

DOI: 10.9734/JPRI/2022/v34i34B36156

## **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here:

<https://www.sdiarticle5.com/review-history/70722>

**Review Article**

**Received 02 February 2022**

**Accepted 05 April 2022**

**Published 26 April 2022**

## **ABSTRACT**

According to ICH Q3A(R), the impurity in a new drug substance is "any component of a new drug substance that is not the chemical entity defined as a new drug substance". As Per ICH Q3B(R), the impurity in a new drug product is "any component of the drug product that is not the drug substance and excipients in the drug product. "The forced degradation studies are used to facilitate the development of analytical methodology, to achieve a better understanding of the drug substance and the drug product stability, and to determine degradation pathways and the degradation products. This study will help to get the most stable formulation. The bioanalytical method development and validation is an essential part in the drug discovery and development. There is need to develop and validate bioanalytical methods, as sponsors have to submit clinical pharmacology, bioavailability, bioequivalence, pharmacokinetic evaluation along with non-human pharmacology and toxicology studies and preclinical studies to regulatory authorities. There are number of spectroscopic methods includes Ultraviolet spectroscopy, Mass spectroscopy, Nuclear magnetic resonance spectroscopy and Chromatographic methods includes HPLC,HPTLC,GC,UPLC as well as hyphenated techniques like LC-MS, LC/ESI-MS, LC-NMR-MS used for identification and characterization of impurities in an API and the drug products forced degradation study to obtain stability data and bioanalytical methods.

The uniqueness of this review is that it describes the detail information and background explaining impurities, forced degradation and bioanalytical method development and validation as well as all literature available regarding development and validation of all said methods for the drugs and the drug products used to treat type 2 diabetes.

\*Corresponding author: E-mail: mahesh\_deshpande11@rediffmail.com, maheshdeshpande83@gmail.com;

**Keywords:** Antidiabetic drugs; impurity profiling; force degradation study; analytical methods; regulatory guidelines.

## ABBREVIATIONS

API	: Active Pharmaceutical Ingredient
BEH	: Bridged Ethylene Hybrid
CE	: Capillary Electrophoresis
DP's	: Degradation Products
ESI/MS	: Electrospray Ionization Mass Spectrometry
FT-IR	: Fourier Transform Infrared
GC-MS	: Gas Chromatography – Mass Spectrometry
GITs	: Genotoxic Impurities
HILIC	: Hydrophilic Interaction Liquid Chromatography
HPLC	: High Performance Liquid Chromatography
HPLC/ESI-MS	: High-performance Liquid Chromatography/Electrospray Ionization Mass Spectrometry
HPTLC	: High Performance Thin Layer Chromatography
ICH	: International Conference on Harmonization
LC/MS/MS	: Liquid Chromatography–Tandem Mass Spectrometry
LC-ESI-MS	: Liquid Chromatography–Electro Spray Ionization Mass Spectroscopy
LC-ESI/MS/MS	: Liquid Chromatography–Electrospray Ionization Tandem Mass Spectrometry
LC-ESI-QT/MS/MS	: Liquid Chromatography–Tandem Mass Spectrometry Using Electrospray Ionization Source And Q-Trap Mass Analyzer
LC-MS	: Liquid Chromatography–Mass Spectrometry
MeOH	: Methanol
MS	: Mass Spectrometry
NDA	: New Drug Application
PDA	: Photodiode Array
PRIs	: Process Related Impurities
QTOF	: Quadrupole-Time-of-Flight
SIAM	: Stability Indicating Assay Method
SFC	: Supercritical Fluid Chromatography
TEA	: Triethylamine
TFA	: Trifluoroacetic Acid
UPLC	: Ultra-Performance Liquid Chromatography

## 1. INTRODUCTION

According to ICH Q3A(R), the impurity in a new drug substance is “any component of a new drug substance that is not the chemical entity defined as a new drug substance”. As Per ICH Q3B(R), the impurity in the new drug product is “any component of the drug product that is not the drug substance and excipients in the drug product.” The impurities in pharmaceuticals are the unwanted chemicals that remain with the active pharmaceutical ingredient (API), or develop throughout formulation development or upon aging of an APIs and formulated API to medicine. The presence of these unwanted chemical even in small amounts may influence the efficacy and safety of pharmaceutical products [1].

There is an ever-increasing interest in impurities present in APIs recently, not only purity profile but also impurity profile has become essential as per various regulatory requirements [2]. Impurity is initial quality issue in pharmaceutical product that would compromise the efficacy of the drug product. Hence any impurity present in the drug product should be absolutely understood each qualitatively and quantitatively, and qualify, if necessary, through toxicological assessment. So, identification, isolation, qualifications of impurities is an important part of drug development and regulatory assessment. The pharmaceutical impurities are unavoidable as a result of no chemical reaction has 100% selectivity and chemical compound is 100% pure. Ever so, it is possible to reduce impurities via synthetic improvement and appreciate preformulation/formulation studies [3].

### Common terms of impurities: [1,2,3]

There are various terms associated with impurities are as follow,

1. Intermediate
2. Penultimate intermediate
3. By-products
4. Transformation products
5. Interaction products
6. Related products
7. Degradation products

1. **Intermediate** - The compounds produced during the synthesis of the desired material are called intermediates, especially when they have been isolated and characterized.
2. **Penultimate intermediate** - This is the last compound in the synthesis chain prior to the production of the final desired compound.
3. **By-product** - The compound produced in the reaction other than the required intermediates. They can occur through a variety of side reactions, such as over reaction, incomplete reaction, demonization and rearrangement, unwanted reactions between starting materials or intermediates with chemical reagents or catalysts.
4. **Transformation products** - This is a relatively nondescript term that relates to theorized and non-theorized products that may be produced in the reaction, which can include synthetic derivatives of by-products. Transformation products are very similar to by-products.
5. **Interaction products** - These products formed either intentionally or unintentionally interaction between various chemicals involved. Two types of interaction products that can be commonly encountered are drug substance–excipient interactions and drug substance container/closure interaction.
6. **Related products** - These are chemically similar to drug substance and may exhibit potentially similar biological activity.
7. **Degradation products** - They are formed by the decomposition of active ingredient or other material of interest by the effect of external factors like heat, light and moisture.

Now a day the ICH, EMA and USFDA have claimed the importance of impurities in the analysis of drug substances. Alternatively going for determination of purity, the identification and quantification of impurities in formulation & bulks are characterized. This is the best approach to designate the Identity, Quality, Safety, Efficacy, Purity, Strength and Stability of an APIs and pharmaceutical formulations. It has become a mandatory requirement in various pharmacopoeias (BP, EP, USP) to include impurities present in drugs in specified amount [4].

### 1.1 Classification of Impurities

The impurities present in new drug substance can be divided in to the chemistry and safety aspects. According to the chemistry aspect the impurities are identified, classified and analytical methods are developed to set their specifications. The safety aspects explain the qualification of the impurities which are not performed at the time of clinical trials and their threshold limit are determined. According to the ICH guidelines the impurities are classified as Organic, Inorganic, and Solvent. This ICH guidance classifies impurities in three classes as Organic, Inorganic and Solvent. Every class and the aspects should be clearly reported related to each impurity for new drug [5] Refer Fig.1.

#### According to ICH Q3A (R2) guidelines, impurities classified as [6]

1. **Organic impurities** can be identified or unidentified, volatile or nonvolatile. They can arise from manufacturing process or storage of new drug substances.
  - Starting materials
  - Byproducts
  - Intermediates
  - Degradation products
  - Reagents, ligands and catalysts
2. **Inorganic impurities** can result from manufacturing process. They are normally known and identified.
  - Reagents, ligands and catalysts
  - Heavy metals and other residual Solvents
  - Inorganic salts
  - Other materials (e.g, filter aid and charcoal)

**3. Residual Solvents** are the volatile organic chemicals used during the manufacturing process or generated during the drug production. They are categorized into three classes with their limits in pharmaceutical products set by the ICH guidelines Q3C. The class 1 solvents includes Benzene, Carbon tetrachloride, 1,1-dichloroethane, 1,2-dichloroethylene and 1,1,1-trichloroethane should be avoided. The class 2 solvents such as methanol, toluene, pyridine, N, N-dimethylformamide and acetonitrile have permitted daily exposure limits (PDEs). The class 3 solvents such as acetone, isopropyl alcohol, butanol, ethanol and ethyl acetate should be limited by GMP or other quality-based requirements [7].


ICH limits for selected list of common organic solvents found as volatile impurities [8].

### 1.2 Elemental Impurity

The elemental impurities in the drug and the drug products such as As, Cd, Cu, Pb, Hg, V and Pt may arise from several sources; they may be added intentionally in synthesis, or may be present as a contaminant, e.g., through interaction with manufacturing equipment, containers and closures. They do not provide therapeutic benefits to the patients; their level should be controlled within acceptable limits in drug product i.e., Permitted Daily Exposure [P.D.E] for each element of toxicological concern and application of risk approach to control elemental impurities in drug product [9].

**Chart 1. list of common organic solvents**

Volatile Organic Impurity	Limits(ppm)	PDE (mg/day)
Acetonitrile	410	4.1
1,4-dioxane	380	3.8
Chloroform	60	0.6
Methylene chloride	600	6.0
Pyridine	200	2.0
1,1,2-trichloroethane	80	0.8



**Fig. 1. Classification of impurities**

They are classified from ICH Q3D and USP;

Class 1: Cd, Pb, As, Hg

Class 2A: Co, V, Ni

Class 2B: Ag, Au, Tl, Pd, Pt, Ir, Os, Rh, Ru

Class 3: Sb, Ba, Li, Cr, Cu, Sn, Ni

Class 4: B, Fe, Zn, K, Ca, Na, Mn, Mg, W, Al

**According to USP impurities classified as;**

1. Impurities in official articles
2. Ordinary impurities
3. Organic volatile impurities

### 1.3 Sources of Impurities

#### 1. Crystallization related impurities

The polymorphism is the term used to denote crystal systems where a substance can exist in numerous crystal packing arrangements, all of which have the same elemental composition. It is also possible to possess a crystal system where the substance exists in numerous crystal packing arrangements, each of which has a different elemental composition; this phenomenon is known as solvatomorphism [10].

#### 2. Stereochemistry related impurities

It is of paramount importance to seem for stereochemistry related compounds i.e. those compounds that have similar chemical structure but different spatial orientation these compounds will be considered impurities within the API [10].

#### 3. Impurities arising during storage

A variety of impurities can originate from during storage condition or shipment of the drug products. The impurities can come from glass, rubber stoppers and plastic packaging materials. Metal oxide like Na<sub>2</sub>O, SiO<sub>2</sub>, CaO, MgO are the main components leached from the glass [11].

#### 4. Mutual interaction amongst ingredients

Most of the vitamins are extremely labile and because of ageing they generate problems of instability in many dosage forms, particularly in liquid dosage forms. A vitamin on degradation doesn't give toxic impurities; on the opposite hand, the potency of active ingredients lowers pharmaceutical specifications [11].

#### 5. Residual solvents

These are organic volatile chemicals used during manufacturing process generating during the

production. They have toxic or environmentally hazardous properties; their complete removal can be very difficult. The gas chromatography is employed for detection of residual solvents because they're mostly volatile in nature [12].

#### 6. Synthetic Intermediates and by products

The impurities in a pharmaceutical compound or a new chemical entity originate mainly during the synthetic process from raw materials, solvents, and intermediate and by products. The raw materials are normally used to manufacture the drug substance that having minor purity. Similarly, solvents utilized in the synthesis are containing the variety of impurities which will change the range from a trace levels to significant amounts that may react with various chemicals utilized in the synthesis to produce the impurities [13].

#### 7. Formulation related impurities

The number of impurities in a drug product can arise out of inert ingredients used to formulate a drug substance. In the process of formulation, a drug substance is subjected to a variety of conditions that may result in its degradation or other deleterious reaction. The solutions and suspensions are potentially susceptible to degradation due to hydrolysis. The water utilized in the formulation cannot only contribute its own impurities; it may also provide a ripe situation for hydrolysis and catalysis. The similar reactions are possible in the other solvents that may be used [14].

#### 8. Functional group related impurities

The ester hydrolysis can be seen in a few drugs viz aspirin, benzocaine, cefotaxime, ethyl paraben, and cefpodoxime proxetil. The oxidative degradation of the drugs that have hydroxyl group directly bonded to an aromatic ring (viz phenol derivatives like catecholamine and morphine), some drugs like hydrocortisone; methotrexate, and, conjugated dienes (viz vitamin A and unsaturated free fatty acids), heterocyclic aromatic rings, nitroso and nitrite derivatives, and aldehydes (especially flavone rings) are all susceptible to oxidative degradation [11,15].

#### 9. Degradation related impurities

The Impurities can also be formed by degradation of the end product during manufacturing of the bulk drugs. The degradation

of penicillin and cephalosporin's are well-known examples of degradation products. The presence of a  $\beta$ -lactam ring, likewise a  $\alpha$ - amino group in the C6/C7 side chain plays a critical role in their degradation [14].

### 10. Method related impurities

The diclofenac sodium in the parenteral formulation containing an impurity; 1-2, 6 dichlorophenyl indole. In diclofenac sodium indolinone derivatives could also be formed due to condition of autoclave (i.e.,  $123 \pm 20^\circ\text{C}$ ) as it induced intramolecular reaction [14].

### 1.4 Regulatory Guidelines Onimpurities [10,14,16]

There are several regulatory guidelines for impurities are given below:

#### 1) ICH Guidelines

- Q1A(R) – Stability testing of new drug substances and products.
- Q3A- Impurities in new drug substances.
- Q3B- Impurities in new drug products.
- Q3C-Guidelines for residual solvents.

Q3D- Guidelines for elemental impurities

#### 2) US-FDA Guidelines

- NDAs- Impurities in new drug substances
- ANDAs - Impurities in new drug substances

#### 3) Australian regulatory guidelines for prescription medicine, Therapeutic Governance

Authority(TGA),Australia

### 1.5 Impurity Profiling [17,18]

The impurity profiling is a common name of analytical activities, the aim of which is the detection, identification, structure elucidation and quantitative determination of the organic and inorganic impurities and also the residual solvents in bulk drug and pharmaceutical formulation. In case of all phases of development, production and stability testing of the drug product, the impurity profiling of an API are a critical quality control variable. It should contain the details of impurities both qualitative and quantitative form. It describes route of investigating impurity related to with an API.

Schematic representation of scheme for impurity profiling of drugs is shown in Fig. 2.




Fig. 2. Schematic representation of scheme for impurity profiling of the drugs

## 2. FORCE DEGRADATION STUDY [19]

The forced degradation studies are used to facilitate the development of analytical methodology, to achieve a better understanding of the drug substance and the drug product stability, and to determine the degradation pathways and the degradation products. This study will help to get most stable formulation. The drug substance and the drug product stability are a critical parameter which may influence purity, potency and safety. There may be a risk in patient's safety by formation of toxic degradation products due to changes in the drug stability. Therefore, how much degradation is sufficient has been a question for pharmaceutical scientist. The degradation of the drug substances between 5% and 20% has been accepted as reasonable for validation of chromatographic assays. As an opinion of some pharmaceutical scientists, acceptable stability limit of 90% of label claim is usual and 10% degradation is ideal for the use in analytical validation for the small drug molecule. The forced degradation study Chart is shown in Fig. 3.

### 2.1 Hydrolytic Condition

The hydrolytic study under the acidic and the basic conditions involves catalysis of ionizable functional groups present in the molecule. Hydrochloric acid or sulfuric acids (0.1–1M) for

the acid hydrolysis and the sodium hydroxide or potassium hydroxide (0.1–1 M) for the base hydrolysis are suggested as a suitable reagent for the hydrolysis.

### 2.2 Oxidation Condition


In the oxidation conditions, the hydrogen peroxide is widely used for the oxidation of the drug substances in forced degradation studies but other oxidizing agents such as metal ions, oxygen, and radical initiators (e.g., azobisisobutyronitrile, AIBN) can also be used.

### 2.3 Photolytic Condition

The photo stability studies are carried out to produce primary degradants of the drug substance by exposure to UV or fluorescent conditions. Samples of the drug substance and solid/liquid drug product should be exposed to a minimum of 1.2 million lxh and 200 W h/m<sup>2</sup> light.

### 2.4 Thermal Condition

The thermal degradation (e.g., dry heat and wet heat) studies are carried out at the exhausting conditions than approved ICH Q1A accelerated testing conditions. The solid-state drug substances and drug products samples should be exposed to the dry and wet heat, while liquid drug products should be exposed to dry heat.



**Fig. 3. Force degradation study**

The International Conference on Harmonization addresses the questions regarding to stability as follows: [20-24]

Q1A(R2) Stability testing of new drug substances and products.

Q1B Photostability testing of new drug substances and products.

Q1C Stability testing for new dosage form

Q1D Bracketing and Matrixing designs for stability testing of new drug substances and drug products

### 3. ANALYTICAL METHODS FOR IDENTIFICATION AND CHARACTERIZATION OF IMPURITY

#### A) Reference standard method:

The main purpose of this method is to quantify and to control reference standards which are used in the process of the development and control of a new drug. As we know that the reference standards allow to understand the fundamental information for evaluation and observing the performance of the bulk drug, by products, impurities, degradation products, excipients, raw materials, intermediates [25].

#### B) Spectroscopic methods

##### a) Ultraviolet-visible

The UV-VIS spectroscopy is based on the absorption of the visible and ultraviolet (UV) radiation in the wavelength range of 200-800 nm. The UV at single wavelength doesn't give sufficient information. To confirm greater selectivity and to induce maximum information about molecule the diode array detectors are used nowadays [25].

##### b) Infrared(IR)

The sample is subjected to electromagnetic radiations which are within the range of  $600\text{ cm}^{-1}$  and  $4000\text{ cm}^{-1}$ . This radiation effects the bonds present in the molecule and then it stretches or causes bending in molecule due to absorption of energy of a specific wavelength. The wavelength at which they're absorbed gives us information about different types of bonds which might be used for knowing the structure of the samples. They are mostly use to characterize the solids and semisolids. It provides though little complex but significant or unique fingerprint of any molecule which can be used for analysis of

samples and thus determining the impurities present [26].

#### c) Raman spectroscopy

It is a spectroscopic technique used to study vibrational, rotational, and other low frequency modes in a system. It relies on the Raman scattering of the monochromatic light usually from a laser, in the visible, near infrared, or near ultraviolet range. The laser light interacts with the photons or other excitations in the system, leading to the energy of the laser photons being shifted to up or down. The shift in energy gives information about the phonon modes in the system [27].

#### C) Mass spectrometry (MS)

The technique, where charged species (ions) are separated and detected according to their mass to charge ratio ( $m/z$ ) is known as Mass spectrometry (MS). The MS is specific highly selective and sensitive methods for molecular analysis provides insights to the structure of the analyte. It is also used for monitoring, characterizing and quantification of the drug related substances in an API. If single method fails to provide necessary selectivity, coupling of this technique with the GC, HPLC, and LC lead to increases the power of the technique when complex samples are to be analyze [28].

#### D) Nuclear magnetic resonance (NMR)

The NMR plays a vital role in identifying low level impurities in bulk drug materials with or without chromatographic isolation. The structural elucidation of impurities in the drug materials mostly involve  $^1\text{H}$  and  $^{13}\text{C}$  experiments, the information obtained from these experiments is sufficient to ascertain the structure of the unknown impurity in the drug material. The introduction of the NMR with on-line coupling to the HPLC reduces the need for preparative isolation of impurities [28].

#### E) Separation methods

##### a) Capillary electrophoresis (CE)

The high separation efficiencies compared to other chromatographic techniques is achieved by the CE for determination of the drug-related impurities. In case, the HPLC technique fails to adequately measure impurities, the CE can be employed, especially for very the polar



compounds. The CE is very useful for the separation of closely related compounds, such as the diastereomers and enantiomers. The various modes of the electrophoresis methods have been developed in combination with the chromatography which are as follows [14,29].

- Capillary zone electrophoresis.
- Capillary gel electrophoresis.
- Micellar electrokinetic capillary chromatography.
- Capillary electro chromatography.
- Capillary isoelectric focusing.
- Capillary isotachopheresis.

#### **b) Gas chromatography (GC)**

The GC technique involves vaporization of the sample and subsequent injection in to the gas chromatographic column. The sample is passed through the column by means of gas flow. The solvent used is an inert gas and the stationary phase is a liquid film coated on a support of used silica or a packed sorbent. The sample in the vapour form moves through the column by adsorption and partition phenomenon. The components within the sample mixture are separated by means of their individual affinity to involve in the adsorption and desorption processes. The separated components are eluted from the column and detected by a suitable detector [14].

#### **c) High pressure liquid chromatography (HPLC)**

The HPLC is especially used for identifying, quantifying and purifying the impurities and each component of a substance. This method establishes itself as a critical method in the field of pharmaceutical analysis for both qualitative and quantitative analysis. The USFDA has made a special attention and directed all the pharmaceutical countries of its state to ensure the quality of its product by using the HPLC before selling to global market. The HPLC is used to elucidate structures and quantitatively determine impurities and degradation products in bulk drug substances and pharmaceutical formulations [11].

#### **d) Thin layer chromatography (TLC)**

The TLC is the technique used for the identification of various components up to a trace amounts. This technique has been used for developing stability-indicating analytical method.

It can be used as a quantitative technique, in conjunction with densitometric detection i.e., high performance thin layer chromatography (HPTLC) for compounds which are difficult to analyze by other chromatographic methods because of the absence of the chromosphere. The TLC is very much used during the initial degradation and stress studies to study the number of degradation products formed. The HPTLC is more sensitive and faster compare to conventional TLC technique [26].

#### **e) Supercritical fluid chromatography (SFC)**

The SFC is considered a normal phase technique because it utilizes the relatively nonpolar, "liquid" carbon dioxide as the bulk of the mobile phase that is used for the analysis and purification of the low to moderate molecular weight, thermally labile molecules. It is often used for the separation of chiral compounds. The SFC primarily uses supercritical CO<sub>2</sub> as an eluent. This compound has an acceptable critical pressure (73.8 bar) and its critical temperature is close to ambient conditions (31.18<sup>o</sup>C) [27].

#### **F) Isolation methods**

These methods are mandatory to separate the impurities for their structural identification. Generally, the chromatographic and non-chromatographic methods are utilized for isolation of impurities before characterization. A list of methods that may use for the isolation of impurities is given below.

- a) Solid phase extraction methods
- b) Liquid- Liquid extraction methods
- c) Accelerated solvent extraction methods
- d) Column chromatography
- e) Flash Chromatography [30]

#### **G) Hyphenated methods**

These methods are receiving great ever attention as utilized for solving various analytical problems. As it combines the separation methods with spectroscopic methods like attachment of the mass spectroscopy with gas chromatography or HPLC, it is being used for both the quantitative and qualitative analysis of unknown compounds in complex products. These methods are necessary tool in identifying minor components like the impurities, degradation products, metabolites in various matrices [30].

There are several hyphenated techniques used are given below;

- a) Gas Chromatography-Mass spectrometry (GC-MS)
- b) Liquid Chromatography-Mass spectrometry (LC-MS)
- c) Liquid chromatography-diode array-Mass spectrometry (LC-DAD-MS)
- d) Liquid chromatography-Nuclear magnetic resonance (LC-NMR)
- e) Liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS)
- f) High performance liquid chromatography-DAD-Mass spectrometry (HPLC-DAD-MS)
- g) High performance liquid chromatography-DAD-Nuclear magnetic resonance-mass spectrometry (HPLC-DAD-NMR-MS)

An antidiabetic agent comprises a chemically and pharmacologically heterogeneous group of the drugs. The target in the treating diabetes mellitus is to prevent excessive rises in blood glucose throughout each successive 24 hours period. In type 1 diabetes, where there is absent or little endogenous beta-cell function, insulin treatment is crucial to prevent diabetic ketoacidosis, and the aim is that the precise replacement of the insulin in the fasting state and after the meals. In type 2 diabetes, a choice of the treatment, including insulin is obtainable. These comprises the drug that increase insulin secretion (Sulfonylurea such as glibenclamide, glipizide, gliclazide, and the meglitinide-like drugs such as repaglinide and nateglinide), that improve the insulin sensitivity (biguanides. metformin and the thiazolidine dione such as rosiglitazone, pioglitazone and

troglitazone), and the drug that reduce the carbohydrate absorption (acarbose). In type 2 diabetes, choice of the therapy depends on the several factors (pregnancy and presence of often used to achieve better control than when one agent is alone e.g. Insulin plus sulfonylurea, sulfonylurea plus metformin). Within each category of the agent, choice is commonly associated with pharmacokinetics consideration [31].

#### 4. REGULATORY REQUIREMENTS FOR PHARMACEUTICAL IMPURITY IDENTIFICATION

According to the ICH, FDA and USP guidelines impurities classified in three categories as, organic impurities, inorganic impurities, and residual solvents and these impurities can be form from variety of sources, as given in Fig. 1. The control of organic impurities in a new drug substance is based on the Maximum Daily Dose and Total Daily Intake (TDI) of the impurities. Table 1. (Provides the ICH threshold for control of organic impurities in a new drug substance). Depending on whether the MDD higher or lower than 2g, organic impurities in a new drug substance at (or greater than) 0.05% or 0.1% require identification. The control of organic impurities in a new drug products are outlined in Table 2. Based on the MDD, the identification thresholds for organic impurities in a new drug product are divided into four groups to give more consideration to low dose drug products. For most the new drug products, the MDD is between 10mg – 2g/day, therefore, any impurities at 0.2% or greater would have to be identified [32].

**Table 1. Reporting, Identification, Qualification thresholds for impurities in a new drug substance according to ICH Q3A (R2) [33]**

Maximum daily dose	Reporting Threshold	Identification Threshold	Qualification Threshold
≤ 2g/day	0.05%	0.10% or 1.0mg per day intake (whichever is lower)	0.15% or 1.0mg per day intake (whichever is lower)
>2g/day	0.03%	0.05%	0.05%

**Table 2. Reporting, Identification, Qualification threshold for Degradation Products in New Drug Products according to ICH Q3B (R2) [34]**

Reporting Thresholds	
Maximum Daily Dose	Threshold
≤ 1g	0.1%
> 1g	0.05%

Identification Thresholds	
Maximum Daily Dose	Threshold
< 1mg	1.0% or 5µg TDI, whichever is lower
1mg – 10mg	0.5% or 20µg TDI, whichever is lower
> 10mg – 2 g	0.2% or 2 mg TDI, whichever is lower
> 2 g	0.10%
Qualification Thresholds	
Maximum Daily Dose	Threshold
< 10 mg	1.0% or 50µg TDI, whichever is lower
10mg – 100mg	0.5% or 200µg TDI, whichever is lower
> 100mg – 2 g	0.2% or 3mg TDI, whichever is lower
> 2 g	0.15%

## 5. BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION

The bioanalytical method development and validation is an essential part in the drug discovery and development. There is need to develop and validate bioanalytical methods, as the sponsors have to submit clinical pharmacology, bioavailability, bioequivalence, pharmacokinetic evaluation along with non-human pharmacology and toxicology studies and preclinical studies to regulatory authorities. The bioanalytical methods are developed in biological matrices such as blood, serum, plasma or urine [35]. The bioanalysis process means analysis of the drugs, metabolites and biomarkers in biological samples, and it involves various steps from the sample collection to sample analysis and data reporting. The sample preparation is very important in the bioanalysis. The robust and stable sample preparation method should be applied to produce the reliable results. To remove the interferences from the sample matrix and to improve analytical system performance are the important role of sample preparation. The sample preparation is intensive and time consuming. The liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the method of choice in bioanalytical laboratories for separation and detection due to high selectivity and high sensitivity of the LC-MS/MS technique. The information known about the analyte chemical structure and their properties is important before the start of bioanalytical work. It has important role in the drug development. During the drug development, bioanalysis is an essential part in pharmacokinetic, pharmacodynamics studies and the toxicological evaluation. Additionally, the bioanalytical method validation is an essential for the quantitative determination of various types of analytes in the biological matrices. The bioanalysis procedure includes sample preparation, analysis, calibration and the data evaluation and reporting. A good sample

preparation and a hyphenated instrumentation are required in modern bioanalysis. In pharmaceutical research companies the process of drug discovery and development of comprehensive bioanalytical methods is very important. In addition, the method validation has an important role in bioanalysis to ensure the quality of the performed method. The bioanalytical method validation is very important for supporting of the new drug applications or biologics license applications [36,37].

1. Bioanalytical method development and validation
2. Before the bioanalytical method development study of analyte chemical structure, pKa value, solubility properties, stability and adsorption properties are carried out.
3. Bioanalytical method developed and validated can be divided into:
  4. 1 Preparation of sample
  5. 2 Bioanalytical method development and establishment of assay procedure and
  6. 3. Application of validated bioanalytical method to the analysis of drug [36]

### 5.1 Bioanalysis

The bioanalysis means the identification and quantification of analytes in the biological samples (blood, plasma, serum, saliva, urine, feces, skin, hair, organ tissue). The bioanalysis is not only detection of small molecules e.g. drugs and metabolites but also identify large molecules e.g. the proteins and peptides. The bioanalysis is well established to support drug discovery and drug development. The bioanalysis has an important role to perform the, pharmacokinetic (PK), pharmacodynamics (PD) and toxicokinetic (TK) studies of a new drugs. It also established in clinical, preclinical and forensic toxicology laboratories. Thus, the bioanalysis is an important in many researches such as the

development of new drugs, forensic analysis, doping control and diagnostic of many diseases [36,38].

## 5.2 Extraction Technique in Drug Bioanalysis

The preparation of sample is a primary step, regularly used sample preparation methods is protein precipitation (PPT), Liquid-liquid extraction (LLE), solid phase extraction (SPE).

Following are the commonly used sample preparation techniques [36].

### Protein precipitation (PPT)

The protein precipitation is fast and simple extraction technique applied for both hydrophilic and hydrophobic compounds. The precipitation is usually induced by addition of a miscible organic solvent (Methanol, acetonitrile, or acetone), salt (aluminium chloride), metal ions (zinc sulphate) or by changing the sample pH to change the nature of the solution (acids such as trichloroacetic, perchloric, metaphosphoric). In some cases, extraction of some drugs and metabolites the protein precipitation method can be followed by LLE or SPE in order to achieve higher efficiency [36].

### Liquid-liquid extraction (LLE)

The LLE has been widely used for the preparation of aqueous and biological samples (e.g. Plasma, urine) also for extraction of the acidic and basic drug from biological samples. The liquid-liquid extraction technique is not suitable for extraction of analytes with different polarity from same sample [36].

### Solid phase extraction (SPE)

The SPE has a high efficiency, cost-effective, high reproducibility, and easy to operate. It is used for separating and concentrating of a trace analytes in biological samples [36].

### Types of SPE techniques

#### 1. Reversed phase- solid phase extraction

This is less selective compared to normal phase or ion-exchange SPE, Methanol, acetonitrile or mixed buffer/solvent are used as elution sample in RP-SPE. The Sorbent used are bonded silica (C4, C8, C18 and Ph, with 40 µm particle size

and 60Å pore size) and polymer sorbent as polystyrene can be used. This technique is used in biological fluids and environmental pollutants in water [36].

#### 2. Normal phase-solid phase extraction

Typical sorbents in NP-SPE are silica with polar functional groups (Si-CN, Si-NH<sub>2</sub>, Si-Diol and pure silica). The retention mechanism in this technique is based on hydrogen bonding between analytes and sorbent [36].

#### 3. Ion exchange-solid phase extraction

It is most selective method in SEE, based on acidic drugs can be isolated with quaternary amine bonded silica or Si-NH<sub>2</sub> as an anion exchange, for basic drugs strong cation exchange, Si-SCX and weak cation exchange, Si-WCX can be used for isolating the cationic analytes [36].

## 5.3 Separation and Detection Instrumentation

### Liquid chromatography-UV (LC-UV)

The high performance liquid chromatography (HPLC) is commonly used technique in bioanalysis. The main detector used in HPLC is UV-visible detector. Due to the wide range of selectivity of HPLC column; it is applied for separation of the drug and many metabolites in different matrices [36].

### Liquid chromatography-tandem mass spectrometry (LC-MS/MS)

Liquid chromatography-tandem mass spectroscopy is having high selectivity as an important tool in drug discovery. It has advantages to reduced analysis time [36].

### Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS)

As compared to the LC, UPLC has many advantages such as higher resolution, high peak capacity, improved sensitivity and high speed of analysis, and reduced the ion suppression. The UPLC is used for smaller particles (<2.5 µm) and higher flow rates [36].

### Supercritical fluid chromatography-Tandem mass spectrometry (SFC-MS/MS)

As compared to the HPLC, SFC has some advantage like rapid separation without using

hazardous organic solvents. The diffusion rate of solute in supercritical fluid is ten times greater than organic solvents in LC. This technique has higher flow rate and higher sample capacity for determination of different drugs and metabolites in biological fluids [36].

#### 5.4 Validation Parameters [39]

##### 1. Linearity

The ability of the method to obtain test result that is directly proportional to the concentration of analyte in the sample. The linearity of the method must be determined regardless of the drug development phase.

##### 2. Selectivity (specificity)

The ability to assess unequivocally the analyte in the presence of expected component, which may consist of excipient, degradant etc. For high performance liquid chromatography (HPLC) identification test, peak purity evaluation should be used to assess the homogeneity of the peak corresponding to the analyte of interest.

##### 3. Calibration model

The selection of an appropriate calibration model is necessary for reliable quantification of components. This can be done by sample analyzing and plotting of response versus corresponding concentration.

##### 4. Precision and repeatability

The repeatability means closeness of agreement of a series of measurements under the same operating conditions over a short interval of time. It can be evaluated by performing a minimum of six replicate of a single sample solution prepared at the 100% test concentration. Intermediate precision performed within-laboratory variations such as different analyte, different days, and different equipment's. The repeatability also termed intra-assay precision and within day precision.

##### 5. Intermediate Precision

The intermediate precision expresses within-laboratories variations: different analytes, different days, different equipment's, etc. Intermediate precision is also called between-day, between-run, or inter-assay precision.

##### 6. Reproducibility

The reproducibility expresses the precision between laboratories; it is usually applied to standardization of methodology. The reproducibility study a proposed method used in different laboratories [39,40].

##### 7. Limit of detection

According to the ICH, limit of detection (LOD) means the lowest concentration of an analyte in a sample which is can be detected but not quantified as an exact value.

##### 8. Limit of quantification

The limit of quantification (LOQ) is the lowest amount of concentration of analyte in a sample that can be quantitatively determined with suitable precision and accuracy [39,41].

##### 9. Robustness

The ruggedness is a measure for the susceptibility of a method to small changes that might occur during the analysis like small changes of (mobile phase composition, temperature, pH values etc). it can be very helpful during the method development/prevalidation phase.

##### Stability

The chemical stability of an analyte in a matrix under specific conditions for given time of intervals. The stability of the analyte during the analytical procedure is a prerequisite for reliable quantification.

*Long term stability*

*Inprocess stability*

#### 6. CLASSIFICATION OF ORAL ANTIDIABETIC DRUGS [42]

##### 1. Enhance Insulin Secretion

A) KATP channel blockers

a) Sulfonylurea – Tolbutamide, Glibenclamide, Glipizide, Gliclazide, Glimepiride

b) Meglitide/Phenylamine analogues – Repaglinide, Nateglinide

B) Dipeptidyl peptidase -4 (DPP-4)inhibitors  
- Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Linagliptin, Teneagliptin

## 2. Overcome InsulinResistance

a) Biguanide (AMPk activator) – Metformin  
b) Thiazolidinedione (PPARyactivator) – Pioglitazone, Troglitazone

## 3. Miscellaneous drugs

a)  $\alpha$  – Glucosidase inhibitors- Acarbose, Miglitol, Voglibose  
b) Amylin analogue -Pramlintide  
c) Dopamine D2 agonist –Bromocriptine  
d) Sod-glucose cotransport-2 (SGPT-2) inhibitors – Dapagliflozin, Canagliflozine, Empagliflozin.

## 7. CATEGORY WISE ANALYTICAL PERSPECTIVES OF ANTIDIABETIC DRUGS

Various drugs from different class of ant diabetic drugs were studied for study related to impurity profiling and force degradation. The study was based on following analytical perspectives.

- **Column**—Column is one of the most important parts of chromatographic techniques where separation of analyte is

performed. Column dimensions, chemistry of column, nature of stationary phase filled in column, particle size of stationary phase are important parameters for separation of different components from a mixture. C18 are widely used column while other C8, Phenyl, Amino, Carbohydrate ES, Cyano, Silica, HILIC column used wherever they are suitable. Fig. 4.

- **Type of elution** – Both Isocratic and Gradient elution are widely used. Fig. 5.
- **Matrix** –Maximum work is carried out on an Active pharmaceutical ingredients followed by Tablets are used for impurity profiling and force degradation study. Fig. 6.
- **Categories** - Anti-diabetic drugs (Oral hypoglycemic agents) categories as Dipeptidyl peptidase -4inhibitors, K-ATP channel blockers, Sulfonylureas, Alpha-Glucosidase inhibitors, Sodium glucose co-transport-2 inhibitors, Biguanide and Thiazolidinedione. The impurity profiling and forced degradation study are carried out on drugs belongs to these categories. Fig. 7.
- **Chromatographic techniques** – The HPLC is widely used technique while UPLC, HILIC, HPTLC are also used for the separation of mixtures. Fig. 8.
- **Detectors** - PDA detector are widely used as compared to UV and MS. Fig. 9.




Fig. 4. Different column used for of Impurity and Forced degradation profiling of Antidiabetic drugs




Fig. 5. Types of Elution performed in analysis for Impurity degradation profiling of Antidiabetic drugs




Fig. 6. Different matrix used for Impurity and Forced degradation profiling of Antidiabetic drug




Fig. 7. Categories of Antidiabetic drugs on which impurity profiling and forced degradation are studied




Fig. 8. Different Chromatographic Technique used for Impurity and Forced degradation profiling of Antidiabetic drugs




Fig. 9. Different detectors used for Impurity and Forced degradation profiling of Antidiabetic drugs



7. Methods of impurity profiling, forced degradation and bioanalytical for oral antidiabetic drugs							
Sr. no	Name of drug	API/dosage form	Impurity/Degradant/Biological Matrix	Chromatographic Conditions		Detection	Year (Ref.)
				Stationary Phase	Mobile Phase		
<b>1.ENHANCE INSULIN SECRETION</b>							
<b>A) KATP channel blockers</b>							
<b>a) Sulfonylurea</b>							
<b>1</b>	<b>Glibenclamide</b>						
	Josephine Tella, et al	Tablet	1 sulfonamide impurity	C <sub>18</sub> stainless steel column (250×4.5 mm, 5µm)	Acetonitrile: potassium dihydrogen orthophosphate (pH3) (43:57v/v) (Isocratic elution)	250nm (UV- Visible)	2019 [43]
	Ehab F Elkady et al	Tablet	Human Plasma	Kromasil 100-C18, (30 × 0.4 cm, 10 µm)	Acetonitrile: 0.05M potassium dihydrogen phosphate (MKP) and 0.01M sodium octane sulphonate (SOS) (pH 3.55). <b>flow rate</b> -0.85 ml/min	220nm (UV)	2015 [44]
<b>2</b>	<b>Glipizide</b>						
	Gulshan Bansal et al	API	6 Degradants	Spherisorb C18 (250×4.6mm, 5µm)	20Mm Ammonium acetate buffer (pH3): CAN (60:40v/v) (Isocratic elution)	230nm LC-MS	2007 [45]
	Anna Gumieniczek et al	API	1 Degradants	Poroshel1 120SB-C18 Column (100×3mm,2.5µm)	0.067M Phosphate buffer(pH4.3): ACN (60:40v/v) (Isocratic)	230nm LC-MS	2013 [46]
	Sakshi Gupta et al	API	4 Degradants	X Terra C18 (250mm×4.5m, 5µm)	A-Buffer (0.005M KH <sub>2</sub> PO <sub>4</sub> , pH3) + methanol (60:40v/v) B – Same as above (20:80v/v) (Gradients)	230nm (UV)	2011 [47]
	Tina M. Binz and et al	API	Serum	UPLC over a C18 column	Waters Xevo TQ MS mass spectrometer LC-MS/MS method	LC-MS/MS	2012 [48]

K.S. Lakshmi et al	API	Human Plasma	phenomenex C18 column (150 × 4.6 mm, i.d., 5 µm)	mixture of 0.05% Triethylamine, acetonitrile and methanol in the ratio of 55:15:30 <b>flow rate:</b> 1 ml min <sup>-1</sup>	248 nm	2011 [49]
<b>3 Gliclazide</b>						
Gulshan Bansal et al	API	6 Degradants	SpherisorbC18 (250×4.6mm, 5µm)	ACN: Ammonium acetate (25mM) (40:60v/v) (Isocratic)	235nm LC/ESI-MS	2008 [50]
<b>4 Glimepiride</b>						
Shraddha Pawar et al	Tablet	Glimepiride related - 3 and Metformin related - 1 Impurity	Water symmetry C8 (4.6mm×250mm,5µm)	A- Pentane sulfonic acid sodium salt buffer(pH3.5) +dil. orthophosphoric acid B- ACN (Gradient)	230nm (PDA)	2010 [51]
Gulshan Bansal et al	API	5Degradants	Spherisorb C18(150mm×4.6m m,5µm)	ACN: Ammonium acetate (pH3;.0.2M) (20:80v/v) (Isocratic)	235nm (PDA) LC-MS	2008 [52]
<b>b) Meglitinide / Phenylalanine analogues</b>						
<b>5 Repaglinide</b>						
Prasad Kancherla, et al	API	7 Impurities	Acuity BEH C18 (100×2.1mm, 1.7µm)	A – mix. Of 0.05% formic acid in water B – mix. Of 0.05% formic acid in ACN (Gradient elution)	UPLC 210nm (UV)	2017 [53]
K.V.S. R Krishna Reddy et al	API	4 Impurities	Hichrome- RPB C18 (250mm×4.6mm,5µm)	0.01M KH <sub>2</sub> PO <sub>4</sub> (pH3.5): CAN(50:50v/v)(Isocratic)	200nm (PDA)	2003 [54]
Jie Zhang and et al	API	Human Plasma	XDB-C18 column	acetonitrile–ammonium acetate buffer	LC-MS/MS)	2011 [55]
<b>B) Dipeptidyl peptidase 4-(DPP-4) inhibitors</b>						
<b>6. Sitagliptin</b>						
P.B.N. Prasad et al.	API	2 Impurities	Unison-US,C8 (150×4.6mm,5µm)	A- mix. Of buffer (pH7.2) and ACN (9:1v/v) B- mix. Of buffer pH7.2 and ACN (7:3v/v)	210nm (PDA)	2018 [56]

F.I Farooqui et al	API	3 Degradants	Water Cosmosil C18 (250×4.6mm,5µm)	(Gradient elution) 5mM Ammonium acetate: methanol (Gradient)	268nm (PDA) MS, NMR	2016 [57]
Dnyaneshwar.P. P et al	API/ Tablet	API-3Tablet-2 Degradants	Agilent PrepHT XDB-C18 (21.2×150mm,5µm)	5mM Ammonium acetate in water:ACN(Gradient)	210nm (PDA)	2013 [58]
Wei Zeng et al	API	Human plasma	Waters Atlantis HILIC Silica column (2.1mm×50mm, 3_µm).	ACN/H2O (80/20v/v)	LC–MS/MS	2010 [59]
MaikeScherf-Clavel et al	API	Human Dried Blood Spot (DBS)			HPLC/UV and LC-ESI–MS/MS	2015 [60]
Srinivasa Reddy et al	API	Human Plasma	SCX column	20mM ammonium acetate(pH4.5): acetonitrile:50:50 v/v)	LC-MS/MS	2015 [61]
<b>7 Vildagliptin</b>						
Neeraj Kumar et al	API	2 PRI	Waters X Bridge C- 18 (250×4.6mm,5µm)	A- 0.05% Ammonia solution(pH 9.2) B- mix. Of methanol and ACN(50:50v/v)(Gradient elution)	210nm (PDA) LC/ESI-MS	2015 [62]
Ramzia I. ElBagary et al	API	Human Plasma	5 cm UPLC-C18 column	0.5% acetic acid in methanol and 0.02 M aqueous ammonium acetate (10:90 v/v)	UPLC-MS/MS	2016 [63]
Roberto Pontarolo et al	API	Human Plasma	Atlantis HILIC Silica 150-mm x 2.1-mm	20% water and 80% acetonitrile/water solution 95:5 (v/v) The flow rate at 400 L min <sup>-1</sup> .	HILIC–MS/MS method	2014 [64]
<b>8. Saxagliptin</b>						
F.I.Farooqui et al	API	3 Degradants	Hypersil BDS C18 (250×4.6mm,5µm)	Water: ACN (Gradient elution)	231nm (PDA)	2016 [65]
<b>9. Alogliptin Benzoate</b>						
Kun Zhangand et al	API	7 PRI	Zorbax SBCN column (250×4.6mm5µm)	A- Water: ACN: Trifluoroacetic	278nm (DAD)	2015 [66]

				acid(1900:100:1v/v/v)B-ACN: Water: Trifluoroacetic acid (1900:100:1v/ v/v)(Gradients) 0.05v/v orthophosphoric acid in water: methanol (60:40v/v)(Gradient)	ESI-MS 210nm (UV-Visible)	2016 [67]
Rajendra Phadke et al	API	1 Genotoxic Impurity (2- bromomethyl)	Hypersil BDSC8 (250×4.6mm,5µm)			
Yuting Lu and et al	API-3 Tablet-2	5 Degradants	Phenomenex Gemini NX C18 (250×4.6mm,5µm)	A-0.2%formic acid+0.2%Ammonium acetate in water B-ACN: Methanol(60:40v/ v)(Gradient)	278nm (PDA) LC-QTOF	2016 [68]
<b>10 Linagliptin</b>						
Sushant B. Jadhav et al	API	3 Degradants	Zorbax SB-Aq(250×4.6mm, 5µm)	A- KH <sub>2</sub> PO <sub>4</sub> buffer (0.02M) pH3 B-ACN: methanol (90:10v/ v) (Gradient elution)	225nm (PDA) LC-MS	2017 [69]
Raquel Balestri et al	Tablet	3 synthetic impurities	Thermo Scientific (RP-8) column (100×4.6mm,5µm)	0.1%formicacid(pH3.5): ACN(Gradient)	294nm (PDA)	2019 [70]
Yiwen Huang et al	API	1 PRI, and 1 Degradant	Water Acquity BEH C18(50×2.1mm, 1.7µm)	A-20mM KH <sub>2</sub> PO <sub>4</sub> B-ACN: methanol(50:50v/ v) (Gradient)	UPLC228nm ESI- MS/MS	2018 [71]
Bashar Al- sabti et al	API	1 Impurity- (3-aminopyridine)	TRACEREXTRASIL silica (150×4mm,3µm)	A-10Mm Ammonium Acetate pH6 in water B-ACN(10:90v/v) (Isocratic)	HILIC- UV 298nm	2020 [72]
Sharmila donepudi, et al	API	Human Plasma	discovery c <sub>18</sub> (250×4.6x5) column,	buffer: acetonitrile (68:32)	218nm (UV)	2018 [73]
<b>11 Teneligliptin</b>						
Ganesh Kumar et al	API	7 Degradants	Kromasil 100-5C18 (250×4.6mm, 5µm)	Phosphate buffer (pH6): ACN(60:40v/v) (Isocratic)	246nm (UV) UPLC- MS/MS	2016 [74]
<b>2.OVERCOME INSULIN RESISTANCE</b>						
<b>a) Biguanide (AM Pk activator)</b>						
<b>12 Metformin HCl</b>						
Rajan.V. Rele et al	Tablet	1 Impurity	Inertsil ODS 3V,	Mix. of Trifluoroacetic acid in	218nm	2018

Gabriela klaczkow et al	Tablet	(N, N-Dimethyl amidino) 3 Impurities	(250×4.6mm, 5µm) PARTISPHERE SCX C18(250×4.6mm,5µm)	Water: ACN (98:2v/v)(Gradient) 1.7%(w/v) ammonium dihydrogen phosphate water solution (pH3.1)(Isocratic) Buffer(pH3.6): ACN (90:10v/v)(Isocratic)	(DAD) 218nm (UV-Visible)	[75] 2010 [76]
T. Sudha et al	Tablet	3 Impurities	Inertsil ODS 3V (250×4.6mm,5µm)	Ammonium dihydrogen phosphate (pH5): Methanol(21:79v/v) (Isocratic)	218nm (UV)	2013 [77]
F.AI.Rimavi et al	Tablet	1 Impurity (1-Cyanoguanidine)	Nova-Pak Silica (150×3.9mm, 4µm)		HPLC- UV 232nm	2009 [78]
Hiren N. Mistriand et al	API	Human Plasma	reverse phase C18 (50mm×4.6mm i.d., 5 µm) column		(LC–MS/MS)	2007 [79]
B. Jagadeesh, D. et al	API	Human Plasma	Reverse Phase		ESI-MS/MS	2013 [80]
Lingyun Chen et al	API	Human Plasma	C18 column (50 mm,2.1 mm, 3.5 µm)	Acetonitrile 10 mM ammonium acetate (20:80,v/v).	tandem mass spectrometry via electrospray ionization.	2011 [81]
Asmaa A. El-Zaher et al	API	Human Plasma	Zorbax C <sub>18</sub> column(50x4.6mm,5m)	acetonitrile: 0.1% formic acid (45:55v/v)	LC-MS/MS	2019 [82]
Srinivasa Rao Polagania et al	API	Human Plasma	Alltima HP C18 column	acetonitrile and 10mM ammonium acetate (pH3.0)60:40(v/v) <b>Flow rate</b> :1.1mL/min.	LC–MS/ MS	2013 [83]
Pawan K. Porwaland et al	API	Human Plasma	Water's Novapack Phenyl (150 mm 4.6 mm, i.d., 5.0 lm) column	0.1% Phosphoric acid (pH 3.0) and acetonitrile (ACN)	227 nm UV	2016 [84]
<b>b) Thiazolidinedione (PPAR<math>\gamma</math> activator)</b>						
<b>13 Pioglitazone</b>						
Y.R Kumar and et	API	3 Impurities	Hichrome RPB column	0.01M KH <sub>2</sub> PO <sub>4</sub> (pH6): ACN	225nm	2004

al			(250×4.6mm,5µm)	(50:50v/v) (Isocratic)	(PDA)	[85]
Gregory A. Knock and et al		In rat	conventional whole cell patch clamp technique	compared the effects of troglitazone and rosiglitazone on Ca <sub>2q</sub> and K <sub>q</sub> currents in rat aorta and pulmonary artery smooth muscle cells. Both drugs reduced the voltage-gated <u>L</u> -type.		1999 [86]
Vijaya Kumari Karraa et al	API	Human Plasma	C18 column	acetonitrile and 0.1%formic acid(80:20(v/v))	LC-MS/MS	2012 [87]
<b>14</b>	<b>Troglitazone</b>					
J.MosesBabu et al	API	8 Impurities	Hypersil BDS C18 (250×4.6mm,5µm)	0.05M ammonium acetate: ACN:Methanol (33:55:12), pH4.5(Isocratic)	254nm (UV) LC-MS	2003 [88]
<b>MISCELLANEOUS DRUGS</b>						
<b>a) α-Glucosidase inhibitors</b>						
<b>15</b>	<b>Acarbose</b>					
Predrag Novak et al	API	3 Impurities	NH <sub>2</sub> Hibar Lichrospher LC Column(250 ×4mm, 5µm)	ACN: Water (71:29 v/v) (Isocratic)	210nm (DAD) LC-MS, LC- NMR	2005 [89]
<b>16</b>	<b>Miglitol</b>					
Kesavan Balakumaran et al	API	6 PRI	Prevail Carbohydrate ES column(250×4.6mm,3.5µm)	A-10mM dipotassium hydrogen orthophosphate in water (pH8) B-CAN (Gradient)	210nmLC- MS	2016 [90]
<b>b) Sodium- glucose cotransporter- 2(SGLT- 2)Inhibitors</b>						
<b>17</b>	<b>Canagliflozin</b>					
Amit Gosar et al	API	1(Potential genotoxic hydrop peroxide impurity)	KromasilC18 (250×4.6mm,5µm)	A-20mMPotassium dihydrogen Phosphate solution: ACN (Gradient)	341nm (UV)	2019 [91]
Somarouthu Venkata saibaba et	API	Human plasma	ZodiacC18(100mm×4.6mm,5µm)	2mM ammonium acetate and methanol(15:85,v/v)	LC-MS/MS	2018 [92]

al						
18	Empagliflozin					
Mokhtar M. Mabrouk et al	API	3 Impurities	Acquity UPLC, BEHC18 (50×2.1mm, 1.7µm)	Trifluoroacetic acid: ACN (60:40v/v) (Isocratic)	210nm UPLC- DAD	2019 [93]
Sushil H. Jaiswal et al	API	4 PRI	Inertsil C8 (250×4.6mm, 5µm)	0.1%Orthophosphoric acid: ACN (Gradient)	230nm PDA	2017 [94]
Varaprasad Jagadabi et al	Tablet	Empagliflozin related-5 Linagliptin related-6 Degradants	Luna Omega Polar C18 (100×2.1mm, 1.6µm)	A-KH <sub>2</sub> PO <sub>4</sub> (pH3) B-ACN: methanol (55:45v/v)(Gradient)	LC-QD a mass detector	2018 [95]
Prakash Niguram et al	API	12Degradants	Eclipse plus C18 RRHD (2.1×50mm, 1.8µm)	Water with 0.1% formic acid: methanol (50:50v/v) (Isocratic)	UHPLC-MS, LC-ESI-QTOF-MS	2019 [96]
Ritesh P.Bhole	Tablet	3 Degradants	10×10 Aluminum plate precoatedwith silica gel	Toluene: methanol(7:3v/v)	228nm HPTLC-MS	2018 [97]

## 8. CONCLUSION

This review article provides information regarding analytical methods used for identification and characterization of impurities and degradation products of antidiabetic drugs. The analytical techniques employed for impurity analysis were the HPLC, UPLC, LC-MS, LC-NMR, HPTLC, and HILIC. Among all these analytical techniques the most widely used technique is the HPLC and LC-MS. This review consequently focuses on basic aspects of impurities in drug substance and drug products, forced degradation and bioanalytical methods which will be helpful to researchers engaged in said areas for the analysis of antidiabetic drugs. Although different regulatory bodies have provided individual guidelines describing identities and permissible limits of all said methods.

## CONSENT

It is not applicable.

## ETHICAL APPROVAL

It is not applicable.

## ACKNOWLEDGEMENT

The authors are very much thankful to Management and Principal Dr.M.J.Chavan of Amrutvahini College of Pharmacy, Sangamner, M.S., India.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Chen KTL, CH. Determination of impurities in pharmaceuticals: Why and how? Intech [Internet]. 2019;1–17.
2. Venkatesan P, Valliappan K. Impurity profiling: Theory and practice. J Pharm Sci Res. 2014;6(7):254–9.
3. Abdin AY, Yeboah P, Jacob C. Chemical impurities: An epistemological riddle with serious side effects. Int J Environ Res Public Health. 2020;17(3):1–13.
4. Jadhav GP, Kasture VS, Pawar SS, Vadgaonkar AR. Drug impurity profiling : A scientific approach. 2014;8(6):696–706
5. Mahesh Mukund Deshpande (September 14th 2020). Analytical, bioanalytical, stability indicating methods: Key part of regulatory submissions [Online First], IntechOpen, DOI: 10.5772/intechopen.93566. Available: <https://www.intechopen.com/online-first/analytical-bioanalytical-stability-indicating-methods-key-part-of-regulatory-submissions>
6. ICH, Impurities in new drug substances Q3A (R2). In: International Conference on Harmonization. IFPMA. Geneva (Switzerland); 2006
7. ICH, Impurities: Guideline for Residual Solvents Q3C (R6), in: International Conference on Harmonization, IFPMA, Geneva (Switzerland); 2016.
8. Savkare AD, Kalaskar PS, Sarode SK, Potkule ME. Recent advances in impurity profiling of pharmaceuticals. Int J Pharm Sci Res. 2017;8(8):3206–17.
9. ICH, Guideline for Elemental impurities Q3D, in: International Conference on Harmonization, IFPMA, Geneva (Switzerland); 2014.
10. Ahuja S. Overview: Isolation and characterization of impurities in pharmaceuticals, separation science and technology. 2004;5:1–25.
11. Dubey S, Kumar Pandey R, Shankar Shukla S., Impurity profiling and drug characterization: Backdrop and approach. Indo Am. J P Sci [Internet]. 2018; 05(04):2499–515.
12. Singh A, Afreen S, Singh DP, Kumar R. A review on pharmaceutical impurities and their importance, World J Pharm Pharm Sci. 2017;6(10):1337–54.
13. Prabu SL, Suriyaprakash TNK. Impurities and its importance in pharmacy, Int J Pharm Sci Rev Res. 2010;3(2):66–71.
14. Nath D, Sharma B. Impurity profiling-a significant approach in pharmaceuticals. Curr Pharm Anal. 2018;15(7):669–80.
15. Warad TA, Bhusnure OG, Gholve SB. Review article impurity profile of pharmaceuticals ingredient: A review. Journal of Pharmacy Research. 2016; 10(7):523–33.
16. United States Pharmacopeia, Impurities in Drug Substances and Drugs Products <1086>. Usp 42–Nf 37 [Internet]. 2019; 41(June):7545.
17. Salunkhe MN, Gite SD, Kachave RN. Recent trends in impurity profiling and forced degradation of antihypertensive



- drugs. *J Liq Chromatogr Relat Technol.* 2017;40(16):813–31.
18. Ramachandra B. Development of impurity profiling methods using modern analytical techniques. *Critical Reviews in Analytical Chemistry.* 2017;47:24–36.
  19. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs - A review, *J Pharm Anal.* 2014;4(3):159–65.
  20. ICH, Stability testing of new drug substances and products Q1A (R2). in: International Conference on Harmonization, IFPMA, Geneva (Switzerland); 2003.
  21. ICH, Stability testing: Photostability testing of new drug substances and products Q1B. 1996.in: International Conference on Harmonization, IFPMA, Geneva (Switzerland).
  22. ICH, Stability testing for new dosage forms Q1C. in: International Conference on Harmonization, IFPMA, Geneva (Switzerland); 1996.
  23. ICH, Bracketing and Matrixing designs for stability testing of new drug substances and products Q1D. in: International Conference on Harmonization, IFPMA, Geneva (Switzerland); 2002.
  24. ICH, Evaluation for stability data Q1E. in: International Conference on Harmonization, IFPMA, Geneva (Switzerland); 2003.
  25. Abhijit Chanda, Ramalakshmi N, CN, Nalini SM. Impurity profiling an emerging trend in Pharmaceuticals: A Review. *World J Pharm Res.* 2018;7(9).
  26. Nagpal S, Karan, Upadhyay A, R. Bhardwaj T, Thakkar A. A review on need and importance of impurity profiling. *Curr Pharm Anal.* 2011;7(1):62–70.
  27. Pilaniya K, Chandrawanshi HK, Pilaniya U, Manchandani P, Jain P, Singh N, Recent trends in the impurity profile of pharmaceuticals, *J Adv Pharm Technol Res.* 2010;1(3):302–10.
  28. Churi SK, Lokhande MV. Impurity profiling of pharmaceutical drugs by various methods. *IOSR J Appl Chem.* 2017;10(07):27–34.
  29. Prajapati P, Agrawal YK. Analysis and impurity identification in pharmaceuticals. *Rev Anal Chem.* 2014;33(2):123–33.
  30. Shreya R. Shah, Mayur A. Patel, Miral V Naik, Pradhan PK, UMU. Department, recent approach of impurity profiling in pharmaceutical analysis: A review. *Int.j.Pharm.research.* 2012;3(10):3603–17.
  31. Pinson R. Antidiabetic agents. *Annu Rep Med Chem.* 1967;2(C):176–86.
  32. Qiu F, Norwood DL. Identification of pharmaceutical impurities. *J Liq Chromatogr Relat Technol.* 2007;30(5–7):877–935.
  33. FDA. Guidance for Industry Q3A (R2) Impurities in New Drug Substances. *Food Drug Adm[Internet].* 2008;Revision 2(June):1–11.
  34. ICH, Impurities in new drug products Q3B (R2). in: International Conference on Harmonization, IFPMA, Geneva (Switzerland); 2006.
  35. Mahesh Mukund Deshpande, Veena Sanjay Kasture, Mahalaxmi Mohan, Macchindra J. Chavan (April 10th 2019). *Bioanalytical Method Development and Validation: A Review, Recent Advances in Analytical Chemistry, Muharrem Ince and Olcay Kaplan Ince, Intech Open.* DOI: 10.5772/intechopen.81620. Available:<https://www.intechopen.com/books/recent-advances-in-analytical-chemistry/bioanalytical-method-development-and-validation-a-review>
  36. Mohammad Mahdi Moein Aziza El Beqqali Mohamed Abdel-Rehim. *Bioanalytical method development and validation: Critical concepts and strategies, Journal of Chromatography B.* 2017;10:433-11,4.
  37. Eeckhaut AV, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects, *Journal of Chromatography. B.* 2009;877:2198–2207
  38. González O, Blanco ME, Iriarte G, Bartolome L, Maguregui MI, Alonso RM. Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect. *J. Chromatogr. A.* 2014;1353 10–27
  39. Gaurav Tiwari, Ruchi Tiwari, *Bioanalytical method validation: An updated review, journal of pharmaceutical methods.* 2010;1:25-38.
  40. Nakashima K. High-performance liquid chromatography of drug of abuse in biological samples. *J Health Sci.* 2009;51:272-7.
  41. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. *AAP J.* 2007;9:E156-63.

42. Tripathi K. Classification of drugs with doses and preparations, 5<sup>th</sup> edition, jaypee brothers; 2014.
43. Tella JO, Oseni SO, Adebayo BK. Physicochemical equivalence and validation of an HPLC analytical method for the quantification of glibenclamide and its sulfonamide impurity in prescribed glibenclamide tablets in Nigeria., J Adv Med Med Res. 2019;29(1):1–17.
44. Ehab F Elkady, Asmaa A El-Zaher, Hanan M Elwy and Mahmoud A Saleh, Validated Liquid chromatographic method for simultaneous determination of metformin, pioglitazone, sitagliptin, repaglinide, glibenclamide and gliclazide - application for counterfeit drug analysis, analytical & bioanalytical techniques, Elkady et al. J Anal Bioanal Tech. 2015;S13.
45. Bansal G, Singh M, Jindal KC, Singh S. LC and LC-MS study on establishment of degradation pathway of glipizide under forced decomposition conditions, J Chromatogr Sci. 2008;46(6):510–7.
46. Gumieniczek A, Berecka A, Pietrań R, Ślebioda M. Stress degradation study of two oral antidiabetics, gliclazide and glipizide, and chemical analysis by LC and LC/MS methods, Cent Eur J Chem. 2014;12(1):80–9.
47. Gupta S, Bansal G., Validated stability-indicating HPLC-UV method for simultaneous determination of glipizide and four impurities, J AOAC Int. 2011;94(2):523–30.
48. Tina M Binz, Nicholas Villani, Hugo Neels, Serge Schneider. Rapid extraction, identification and quantification of oral hypoglycemic drugs in serum and hair using LC–MS/MS, Forensic Science International. 2012;223:119–124.
49. Lakshmi KS, Rajesh T. Development and validation of RP-HPLC method for simultaneous determination of glipizide, rosiglitazone, pioglitazone, glibenclamide and glimepiride in pharmaceutical dosage forms and human plasma. J. Iran. Chem. Soc. 2011;8(1):31-37.
50. Bansal G, Singh M, Jindal KC. Journal of liquid chromatography & related technologies characterization of mass ionizable degradation products of gliclazide by LC / ESI-MS. J Liq Chromatogr Relat Technol. 2008;31:2174–93.
51. Pawar S, Meshram. G, Jadhav R, Bansal Y. Simultaneous determination of Glimepiride and Metformin hydrochloride impurities in sustained release pharmaceutical drug product by HPLC, Chem Der Pharma. 2010;2(4):157–68.
52. Bansal G, Singh M, Jindal KC, Singh S. LC-UV-PDA and LC-MS studies to characterize degradation products of glimepiride, J Pharm Biomed Anal. 2008;48(3):788–95.
53. Kancherla P, Keesari S, Alegete P, Khagga M, Das P. Identification, isolation, and synthesis of seven novel impurities of anti-diabetic drug Repaglinide, Drug Test Anal. 2018;10(1):212–21.
54. Reddy KVS RK, Babu JM, Mathad VT, Eswaraiiah S, Reddy MS, Dubey PK, et al. Impurity profile study of repaglinide. J Pharm Biomed Anal. 2003;32(3):461–7.
55. Jie Zhanga, Feng Gaoa, Xin Guana, Yantong Sunab, Jing-kai Guan J, Paul Fawcett. Determination of repaglinide in human plasma by high-performance liquid chromatography–tandem mass spectrometry, Acta Pharmaceutica Sinica B. 2011;1(1):40–45.
- Vijaya Kumari Karraa, Nageswara Rao Pillia, Jaswanth Kumar Inamadugub JVLN, Seshagiri Rao. Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study, Journal of Pharmaceutical Analysis. 2012;2(3):167–173
56. Prasad PBN, Satyanarayana K, Mohan GK. Impurity profiling and regulatory aspects of sitagliptin active pharmaceutical ingredient. 2018;(2):8–13.
57. Farooqui FI, Kakde RB., Reversed-phase liquid chromatography with mass detection and characterization of sitagliptin degradation related impurities, JPSR. 2016; 7(10):4240-5.
58. Degradation F, Validation M, Mone MK, Facility DD, Towers Q, Gandhi R, et al. and Development of Validated Stability-Indicating Hplc Assay Method. 2013;4(9):3494–503.
59. Wei Zeng, Yang Xu, Marvin Constanzer, Eric J Woolf, Determination of sitagliptin in human plasma using protein precipitation and tandem mass spectrometry, Journal of Chromatography B. 2010;878:1817–1823.
60. Maike Scherf-Clavel, Petra Hogger. Analysis of metformin, sitagliptin and creatinine in human dried blood

- spots, *Journal of Chromatography B*. 2015;997:218–228.
61. Srinivasa Reddy, Imran Ahmed, Iqbal Ahmad, Arindam Mukhopadhyay, Saral Thangam. Development and validation of a method for simultaneous estimation of metformin and sitagliptin in human plasma by LC–MS-MS and its application in a bioequivalence study. *Journal of Chromatographic Science*. 2015;53:1549–1556.
  62. Kumar N, Devineni SR, Singh G, Kadirappa A, Dubey SK, Kumar P. Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin, *J Pharm Biomed Anal*. 2016;119:114–21.
  63. Ramzia I ElBagary, Hassan ME Azzazy, Ehab F ElKady, Faten Farouk. Simultaneous determination of metformin, vildagliptin, and 3-amino-1-adamantanol in human plasma Application to pharmacokinetic studies, *Journal of Liquid Chromatography & Related Technologies*. 2016;39(4):195–202.
  64. Roberto Pontarolo, Ana Carolina Gimenez, Thais Martins Guimarães de Francisco, Rômulo Pereira Ribeiro, Flávia Lada Degaut Pontes, João Cleverson Gasparetto. Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC–MS/MS method, *Journal of Chromatography B*. 2014;965:133–141.
  65. Farooqui FI, Kakde RB. Reversed-phase liquid chromatography with mass detection and characterization of saxagliptin degradation related impurities, *IJPSR*. 2016;8(7):509–14.
  66. Zhang K, Ma P, Jing W, Zhang X., A developed HPLC method for the determination of Alogliptin Benzoate and its potential impurities in bulk drug and tablets. *Asian J Pharm Sci*. 2015;10(2):152–8.
  67. Phadke R, Gaitonde VD. A rapid and sensitive validated reverse phase high performance liquid chromatography method for determination of genotoxic impurity 2-(Bromomethyl)benzotrile in Alogliptin Benzoate, *IJPSR*. 2016;4(7):803-16
  68. Lu Y, Yang D, Li Z, Hang T, Song M. Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques, *J Pharm Biomed Anal [Internet]*. 2016; 128:253–63.
  69. Jadhav SB, Reddy PS, Narayanan KL, Bhosale PN. Development of RP-HPLC, stability indicating method for degradation products of linagliptin in presence of metformin HCL by applying 2 level factorial design; and identification of impurity-VII, VIII and IX and synthesis of impurity-VII. *Sci Pharm*. 2017;85(3):1–17.
  70. Heleno Ferreira RB, Duarte JA, Ferreira FD, Oliveira LFS De, Machado MM, Malesuik MD, et al, Biological safety studies and simultaneous determination of linagliptin and synthetic impurities by LC-PDA, *J Anal Methods Chem*. 2019; 2019.
  71. Huang Y, Lu H, Zhang F, Min C. Identification, isolation, characterization, and UHPLC quantification of potential genotoxic impurities in linagliptin, *J Sep Sci*. 2018;41(21):3985–94.
  72. Al-Sabti B, Harbali J., Quantitative determination of potential genotoxic impurity 3-aminopyridine in linagliptin active pharmaceutical ingredient using HILIC–UV, *Biomed Chromatogr*. 2020;34(11):0–2.
  73. Sharmila Donepudi, Suneetha Achanta, Validated HPLC-UV method for simultaneous estimation of linagliptin and empagliflozin in human plasma, *international journal of applied pharmaceuticals*. 2018;10.
  74. Ganesh Kumar TNV, Vidyadhara S, Narkhede NA, Sai Silpa Y, Rajya Lakshmi M. Method development, validation, and stability studies of teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy. *J Anal Sci Technol [Internet]*. 2016;7(1):1–8.
  75. Rele R V, Patil SP. Identification, Isolation and characterization of unknown impurity in metformin hydrochloride. *Chem Sci Trans*. 2014;8(7):6–11.
  76. Kłaczko G, Anuszevska EL. Determination of impurities in medical products containing metformin hydrochloride, *Acta Pol Pharm - Drug Res*. 2010;67(6):593–8.
  77. T, Sudha Vamsi Krishna VR. A validated stability indicating reverse phase liquid chromatography method for metformin HCl and its impurities in bulk and pharmaceutical dosage form. *Res Rev J Pharm Anal [Internet]*. 2013;3(1):27–33.
  78. Al-Rimawi F. Development and validation of an analytical method for metformin

- hydrochloride and its related compound (1-cyanoguanidine) in tablet formulations by HPLC-UV, *Talanta*. 2009;79(5):1368–71.
79. Hireen N Mistri, Arvind G Jangid, Pranav S Shrivastav. Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*. 2007;45:97–106.
  80. Jagadeesh B, Vijaya Bharathi D, Pankaj C, Satya Narayana V, Venkateswarulu V. Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxy pioglitazone and metformin in human plasma by LC–MS/MS: Application to a pharmacokinetic study, *Journal of Chromatography B*. 2013;930:136–145.
  81. Lingyun Chen, Zhifeng Zhou, Mei Shen, Ande Ma, Simultaneous determination and pharmacokinetic study of metformin and rosiglitazone in human plasma by HPLC–ESI-MS. *Journal of Chromatographic Science*. 2011;49.
  82. Asmaa A El-Zaher, Hanaa A Hashem, Ehab F Elkady, Marwa A Allam. A validated LC-MS/MS bioanalytical method for the simultaneous determination of dapagliflozin or saxagliptin with metformin in human plasma. *Microchemical Journal*. 2019;149:104017.
  83. Srinivasa Rao Polagania, Nageswara Rao Pillib, Ramakrishna Gajulab, Venkateswarlu Gndu. Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC–MS/MS and its application to a human pharmacokinetic study, *Journal of Pharmaceutical Analysis*. 2013;3(1): 9–19.
  84. Pawan K Porwal, Gokul S Talele. Development of validated HPLC-UV method for simultaneous determination of Metformin, Amlodipine, Glibenclamide and Atorvastatin in human plasma and application to protein binding studies, *Bulletin of Faculty of Pharmacy, Cairo University*; 2016.
  85. Kumar YR, Reddy AR, Eswaraiah S, Mukkanti K, Reddy MSN, Suryanarayana MV. Structural characterization of impurities in pioglitazone, *Pharmazie*. 2004;59(11):836–9.
  86. Gregory A Knock, Santosh K Mishra, Philip I Aaronson. Differential effects of insulin-sensitizers troglitazone and rosiglitazone, onion currents in rat vascular myocytes, *European Journal of Pharmacology* 368 \_1999. 103–109.
  87. Vijaya Kumari Karraa, Nageswara Rao Pillia, Jaswanth Kumar Inamadugub JVLN, Seshagiri Rao. Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study, *Journal of Pharmaceutical Analysis*. 2012;2(3):167–173
  88. Moses Babu J, Nageshwar D, Ravindra Kumar Y, Prabhakar C, Sarma MR, Om Reddy G, et al. Structural studies on the impurities of troglitazone, *J Pharm Biomed Anal*. 2003;31(2):271–81.
  89. Novak P, Cindrić M, Tepeš P, Dragojević S, Ilijaš M, Mihaljević K. Identification of impurities in acarbose by using an integrated liquid chromatography-nuclear magnetic resonance and liquid chromatography-mass spectrometry approach, *J Sep Sci*. 2005;28(13):1442.
  90. Balakumaran K, Janagili M, Rajana N, Papureddy S, Anireddy J. Development and validation of miglitol and its impurities by RP-HPLC and characterization using mass spectrometry techniques, *Sci Pharm*. 2016;84(4):654–70.
  91. Gosar A, Shaikh T, Botkondle S, Mahadik N, Tole R., Development and validation of HPLC method for determination of trace level potential genotoxic hydroperoxide impurity in canagliflozin. *Int J Pharma Res Heal Sci*. 2019;7(5):3068–71.
  92. Somarouthu Venkata Saibaba N, Nageswara Rao Pilli, Bhavani Prasanna Kumar Bimireddy. Pitchaimuthu shanmuga pandiyan, a novel and rapid LC-MS/MS assay method for the determination of canagliflozin in human plasma by solid phase extraction technique and its application to a pharmacokinetic study, *future journal of pharmaceutical science*. 2018;4:131-138.
  93. Mabrouk MM, Soliman SM, El- Agizy HM, Mansour FR. A UPLC/DAD method for simultaneous determination of empagliflozin and three related substances in spiked human plasma. *BMC Chem [Internet]*. 2019;13(1):1–9.
  94. Jaiswal SH. Validated stability indicating hplc method for determination of process related impurities in empagliflozin drug

- substances. *World J Pharm Res.* 2017;6(7):1025–37.
95. Jagadabi V, Nagendra Kumar P V, Pamidi S, Ramaprasad LA, Nagaraju D. A novel stability –indicating RP-UPLC method for the quantification of impurities and new QDa mass detector coupled with LC-PDA for identification of mass od degradation products in a fixed dose combination of empagliflozin and linagliptin tablet used. *Int Res J Pharm.* 2018;9(7):192–201.
96. Niguram P, Kate AS. Structural characterization of forced degradation products of empagliflozin by high resolution mass spectrometry. *J Liq Chromatogr Relat Technol [Internet].* 2019;42(13–14):417–28.
97. Bhole RP, Tamboli FR. Development and validation of stability indicating HPTLC-MS method for estimation of empagliflozin in pharmaceutical dosage form. *Anal Chem Lett.* 2018;8(2):244–56.

---

© 2022 *Deshpande et al.*; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/70722>